The impact of abiraterone and enzalutamide on hypokalemia incidence in patients with prostate cancer: a systematic review and meta-analysis

• by Yibo Lou, Dejun Fan, Tiejiang Chen, Kai Xiong

• July 2, 2026

Identification of key genes potentially associated with bladder cancer development by common plasticizers: an integrated transcriptomics and network toxicology study

• by Qiuqiu Zhang, Kailiang Xu, Zhongjun Chen, Zihui Li, Dong Zhao

• July 1, 2026

ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer

Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity and manageable side effects.

• July 1, 2026

• 1 min

Targeting the E2F6-TOP2A-DKK1 axis: a novel therapeutic strategy for EMT-driven hepatocellular carcinoma progression

• by Mindan Xing, Yi Lu, Yan Guo, Yantao Jiang, Hengqi Liu, Junjie Yu, Luyao Tong, Zhongyu Wang, Chao Li, Xing Chen, Wei Luo

• July 2, 2026